• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by ADMA Biologics Inc

    9/23/24 4:27:17 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADMA alert in real time by email
    SC 13G 1 ADMA_SC13G_Sept2024.htm SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G
    Under the Securities Exchange Act of 1934


    ADMA BIOLOGICS, INC.
    (Name of Issuer)

    COMMON STOCK, PAR VALUE $0.0001 PER SHARE
    (Title of Class of Securities)

    000899104
    (CUSIP Number)

    SEPTEMBER 19, 2024
    (Date of event which requires filing of this statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

         o Rule 13d-1(b)

         þ Rule 13d-1(c)

         o Rule 13d-1(d)

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the notes).



                         
    CUSIP No.
     
    000899104

    SCHEDULE 13G

    Page  
    2
      of   
    10

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     1,374,038 (See Item 4(a))
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     1,374,038 (See Item 4(a))
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     1,374,038 (See Item 4(a))
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     0.6%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    000899104

    SCHEDULE 13G

    Page  
    3
      of   
    10

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Group Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     1,374,038 (See Item 4(a))
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     1,374,038 (See Item 4(a))
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     1,374,038 (See Item 4(a))
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     0.6%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    000899104

    SCHEDULE 13G

    Page  
    4
      of   
    10

    1
     NAMES OF REPORTING PERSONS
     
     Israel A. Englander
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     1,374,038 (See Item 4(a))
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     1,374,038 (See Item 4(a))
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     1,374,038 (See Item 4(a))
    10
     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     0.6%
    12
     TYPE OF REPORTING PERSON

     IN

                         
    CUSIP No.
     
    000899104

     SCHEDULE 13G

    Page  
    5
      of   
    10
     
    Item 1.    
     
    (a) Name of Issuer:
     
       
     
      ADMA Biologics, Inc.
     
       
     
    (b) Address of Issuer’s Principal Executive Offices:
     
       
     
     

    465 State Route 17
    Ramsey, New Jersey 07446

         
    Item 2.
    (a) Name of Person Filing:
     
    (b) Address of Principal Business Office:
     
    (c) Citizenship:
         
     
      Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Millennium Group Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Israel A. Englander
    c/o Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: United States
     
       
      (d) Title of Class of Securities:
    common stock, par value $0.0001 per share ("Common Stock")
     
      (e) CUSIP Number:
    000899104
     
     

    Item 3.  If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

     
      (a)   o   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
                 
     
      (b)   o   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
                 
     
      (c)   o   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
                 
     
      (d)   o   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
                 
     
      (e)   o   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
                 
     
      (f)   o    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

                         
    CUSIP No.
     
    000899104

     SCHEDULE 13G

    Page  
    6
      of   
    10
                 
     
      (g)   o   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
                 
     
      (h)   o   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
                 
     
      (i)   o   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
                 
     
      (j)   o   Group, in accordance with §240.13d-1(b)(1)(ii)(J).

    Item 4. Ownership

       Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount Beneficially Owned:

       See response to Item 9 on each cover page.

       After acquiring beneficial ownership of more than 5% of the outstanding Common Stock on September 19, 2024, the reporting persons ceased to be beneficial owners of more than 5% of the outstanding Common Stock by the date of this filing.

    (b) Percent of Class:   

       See response to Item 11 on each cover page.

     (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote

       See response to Item 5 on each cover page.


                         
    CUSIP No.
     
    000899104

     SCHEDULE 13G

    Page  
    7
      of   
    10

    (ii) Shared power to vote or to direct the vote

       See response to Item 6 on each cover page.

    (iii) Sole power to dispose or to direct the disposition of

       See response to Item 7 on each cover page.

    (iv) Shared power to dispose or to direct the disposition of

       See response to Item 8 on each cover page.

       The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

    Item 5. Ownership of Five Percent or Less of a Class

       If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following þ.

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

        Not applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

        Not applicable.

    Item 8. Identification and Classification of Members of the Group

        See Exhibit I.

    Item 9. Notice of Dissolution of Group

        Not applicable.

    Item 10. Certification 

       By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


                         
    CUSIP No.
     
    000899104

    SCHEDULE 13G

    Page  
    8
      of   
    10

    Exhibits:

    Exhibit I:  Joint Filing Agreement, dated as of September 20, 2024, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.


                         
    CUSIP No.
     
    000899104

    SCHEDULE 13G

    Page  
    9
      of   
    10
                         
         

    SIGNATURE

                 

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

    Dated: September 20, 2024

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander



                         
    CUSIP No.
     
    000899104

    SCHEDULE 13G

    Page  
    10
      of   
    10
                         
          EXHIBIT I              
                         
          JOINT FILING AGREEMENT              

    This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.0001 per share, of ADMA Biologics, Inc. will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

    Dated: September 20, 2024

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander


    Get the next $ADMA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADMA

    DatePrice TargetRatingAnalyst
    4/21/2026$21.00Buy
    Canaccord Genuity
    3/26/2026Overweight → Neutral
    Cantor Fitzgerald
    7/19/2023$5.00Strong Buy
    Raymond James
    10/13/2022$5.00Buy
    Mizuho
    11/11/2021$5.00Outperform → Strong Buy
    Raymond James
    11/9/2021$4.50Overweight
    Cantor Fitzgerald
    10/26/2021$6.00 → $5.00Outperform
    Raymond James
    8/12/2021$7.00 → $6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ADMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update

    1Q 2026 Total Revenue of $114.5 Million, Flat Year-Over-Year  1Q 2026 ASCENIV Revenue +28% Year-Over-Year; BIVIGAM Revenue -54% Year-Over-Year 1Q 2026 Adjusted Net Income(1) of $40.7 Million, 22% Year-Over-Year Growth 1Q 2026 Adjusted EBITDA(2) of $59.7 Million, Representing 24% Year-Over-Year Growth 1Q 2026 Cash from Operations of $58 Million Highlights Strong Cash Generation Strong Balance Sheet and Financial Flexibility Support Continued Execution Reiterates Confidence in ASCENIV Growth Outlook Driven by Durable Demand Fundamentals Updates FY 2026 Outlook and Withdraws Long-Term Guidance to Reflect Evolving U.S. Plasma Products and IG Market Competitive Dynamics RAMSEY, N.J. and

    5/6/26 4:05:00 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older

    RAMSEY, N.J. and BOCA RATON, Fla., May 04, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced the U.S. Food and Drug Administration ("FDA") has approved the Company's supplemental Biologics License Application (BLA) submitted under section 351(a) of the Public Health Service Act for ASCENIV™. The FDA approval represents the final study report for the Pediatric assessment as required in the post marketing commitment. Additionally, the approval provides for a revision of ASCENIV's prescribing information t

    5/4/26 7:00:00 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026

    RAMSEY, N.J. and BOCA RATON, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that it will report first quarter 2026 financial results on May 6, 2026, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and uniq

    4/29/26 7:00:00 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMA
    SEC Filings

    View All

    ADMA Biologics Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)

    6/2/26 4:05:29 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by ADMA Biologics Inc

    10-Q - ADMA BIOLOGICS, INC. (0001368514) (Filer)

    5/6/26 5:16:25 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ADMA Biologics Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)

    5/6/26 4:10:40 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on ADMA Biologics with a new price target

    Canaccord Genuity initiated coverage of ADMA Biologics with a rating of Buy and set a new price target of $21.00

    4/21/26 7:30:27 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ADMA Biologics downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded ADMA Biologics from Overweight to Neutral

    3/26/26 8:39:56 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Raymond James resumed coverage on ADMA Biologics with a new price target

    Raymond James resumed coverage of ADMA Biologics with a rating of Strong Buy and set a new price target of $5.00

    7/19/23 9:02:26 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Grossman Jerrold B bought $50,624 worth of shares (6,400 units at $7.91), increasing direct ownership by 1% to 520,284 units (SEC Form 4)

    4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)

    5/28/26 4:05:25 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Grossman Jerrold B bought $100,125 worth of shares (12,500 units at $8.01), increasing direct ownership by 2% to 513,884 units (SEC Form 4)

    4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)

    5/14/26 7:00:16 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Grossman Jerrold B bought $100,125 worth of shares (12,500 units at $8.01), increasing direct ownership by 3% to 501,384 units (SEC Form 4)

    4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)

    5/12/26 5:22:51 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Grossman Jerrold B bought $50,624 worth of shares (6,400 units at $7.91), increasing direct ownership by 1% to 520,284 units (SEC Form 4)

    4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)

    5/28/26 4:05:25 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Grossman Jerrold B bought $100,125 worth of shares (12,500 units at $8.01), increasing direct ownership by 2% to 513,884 units (SEC Form 4)

    4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)

    5/14/26 7:00:16 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Grossman Jerrold B bought $100,125 worth of shares (12,500 units at $8.01), increasing direct ownership by 3% to 501,384 units (SEC Form 4)

    4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)

    5/12/26 5:22:51 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMA
    Financials

    Live finance-specific insights

    View All

    ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update

    1Q 2026 Total Revenue of $114.5 Million, Flat Year-Over-Year  1Q 2026 ASCENIV Revenue +28% Year-Over-Year; BIVIGAM Revenue -54% Year-Over-Year 1Q 2026 Adjusted Net Income(1) of $40.7 Million, 22% Year-Over-Year Growth 1Q 2026 Adjusted EBITDA(2) of $59.7 Million, Representing 24% Year-Over-Year Growth 1Q 2026 Cash from Operations of $58 Million Highlights Strong Cash Generation Strong Balance Sheet and Financial Flexibility Support Continued Execution Reiterates Confidence in ASCENIV Growth Outlook Driven by Durable Demand Fundamentals Updates FY 2026 Outlook and Withdraws Long-Term Guidance to Reflect Evolving U.S. Plasma Products and IG Market Competitive Dynamics RAMSEY, N.J. and

    5/6/26 4:05:00 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026

    RAMSEY, N.J. and BOCA RATON, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that it will report first quarter 2026 financial results on May 6, 2026, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and uniq

    4/29/26 7:00:00 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

    RAMSEY, N.J. and BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that it will report fourth quarter and full year 2025 financial results on February 25, 2026, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call seamlessly, participants are required to register for the call here to receive the dial

    2/18/26 7:00:00 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ADMA Biologics Inc

    SC 13G/A - ADMA BIOLOGICS, INC. (0001368514) (Subject)

    11/12/24 1:34:17 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by ADMA Biologics Inc

    SC 13G - ADMA BIOLOGICS, INC. (0001368514) (Subject)

    11/8/24 9:21:37 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by ADMA Biologics Inc

    SC 13G - ADMA BIOLOGICS, INC. (0001368514) (Subject)

    11/4/24 11:00:41 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMA
    Leadership Updates

    Live Leadership Updates

    View All

    ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income(1) of $161 Million, Representing 35% Year-Over-Year Growth FY 2025 Adjusted EBITDA(2) of $231 Million, Representing 40% Year-Over-Year Growth Incoming CFO Appointment Expected to Further Enhance Financial Strategy, Working Capital Execution and Capital Allocation Discipline Advancing SG-001 Pipeline Program with Anticipated FDA Pre-IND Meeting in 2026; Potential Accelerated Path to Registrational Trial Ongoing Share Repurchases and Capital Structure to Increase Stockholder Value Reiterating Previo

    2/25/26 4:05:00 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ADMA Biologics Set to Join S&P SmallCap 600 Index

    RAMSEY, N.J. and BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced it will join the S&P SmallCap 600 index, effective prior to the open of trading on Monday, September 23, 2024. The S&P SmallCap 600 seeks to measure the small-cap segment of the U.S. equity market. "ADMA's inclusion in the S&P SmallCap 600 index is a significant milestone for our company," Adam Grossman, President and Chief Executive Officer of ADMA. "We expect this inclusion will increase our visibility within the investment communit

    9/17/24 7:00:00 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

    9/6/24 6:43:00 PM ET
    $AAL
    $ADMA
    $ADNT
    Air Freight/Delivery Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care